@article{9c76246d713d494fb052ef94f0f0f148,
title = "REM sleep muscle activity in idiopathic REM sleep behavior disorder predicts phenoconversion",
abstract = "Objective To determine whether REM sleep without atonia (RSWA) during polysomnography (PSG) predicts phenoconversion in patients with idiopathic REM sleep behavior disorder (iRBD), a prodromal feature of a neurodegenerative disease. Methods We analyzed RSWA in 60 patients with iRBD, including manual phasic, tonic, and any muscle activity in the submentalis and anterior tibialis muscles and the automated REM atonia index in the submentals. We identified patients who developed parkinsonism or mild cognitive impairment (MCI) during at least 3 years of follow-up after PSG. Kaplan-Meier analysis was performed and receiver operator curves were calculated to determine RSWA cutoffs predicting faster phenoconversion. Results Twenty-six (43%) patients developed parkinsonism (n = 17) or MCI (n = 9). Phenoconverters were older at iRBD diagnosis (p = 0.02). Median time to phenoconversion was 3.9 ± 2.5 years. iRBD phenoconverters had significantly more RSWA at diagnosis. Phenoconversion risk from iRBD diagnosis was 20% and 35% at 3 and 5 years, respectively, with greater risk in patients with iRBD with >46.4% any combined RSWA, which increased further to 30% and 55% at 3 and 5 years for patients >65 years of age at diagnosis. Conclusion sPatients with iRBD with higher amounts of polysomnographic RSWA had a greater risk of developing Parkinson disease or MCI. Patients with older age and higher RSWA amounts had more rapid phenoconversion than younger patients with RBD. Our study suggests that RSWA is a potential biomarker for risk stratification of iRBD phenoconversion that could facilitate prognostication for patients with iRBD.Classification of evidenceThis study provides Class II evidence that for patients with iRBD, increased RSWA correlates with increased risk for developing parkinsonism or MCI.",
author = "McCarter, {Stuart J.} and Sandness, {David J.} and McCarter, {Allison R.} and Feemster, {John C.} and Teigen, {Luke N.} and Timm, {Paul C.} and Boeve, {Bradley F.} and Silber, {Michael H.} and {St Louis}, {Erik K.}",
note = "Funding Information: Funded by the Parkinson's Disease Foundation–American Parkinson Disease Association Summer Student Fellowship PDF-APDA-SFW-1656 and Mayo Clinic Alzheimer's Disease Research Center Grant Award from the National Institute on Aging (P50 AG016574), and the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH, through grant 1 UL1 RR024150-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or Parkinson's Disease Foundation–American Parkinson Disease Association. Funding Information: Research Support from Mayo Clinic CCaTS through grant number UL1 TR000135 from the National Center for Advancing Translational Science (NCATS), a component of the National Institutes of Health (NIH). Funding Information: S. McCarter reports that he received grant funding from a Parkinson's Disease Foundation–American Parkinson Disease Association Summer Student Fellowship (PDF-APDA-SFW-1656). D. Sandness, A. McCarter, J. Feemster, L. Teigen, and P. Timm report no disclosures relevant to the manuscript. B. Boeve reports that he is an investigator in clinical trials sponsored by Axovant and GE Healthcare. He receives royalties from the publication of Behavioral Neurology of Dementia (Cambridge Medicine, 2017). He receives research support from grants U01 AG045390, U54 NS092089, P50 AG016574, UO1 AG006786, RO1 AG015866, RO1 AG032306, and RO1 AG041797; the Mangurian Foundation; and the Little Family Foundation. M. Silber reports no disclosures relevant to the manuscript. E. St. Louis reports that he receives research support from the Mayo Clinic Center for Translational Science Activities, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH, through grant 1 UL1 RR024150-01; from the Mayo Clinic Alzheimer's Disease Research Center Grant Award from the National Institute on Aging (P50 AG016574); from the Michael J. Fox Foundation; and from Sunovion, Inc. He has also served as a consultant for Axovant, Inc but receives no personal fees. Go to https://n.neurology.org/lookup/doi/10.1212/WNL.0000000000008127 for full disclosures. Funding Information: Grant support as an investigator in clinical trials funded by Biogen, 2018-present. Publisher Copyright: {\textcopyright} 2019 American Academy of Neurology.",
year = "2019",
month = sep,
day = "17",
doi = "10.1212/WNL.0000000000008127",
language = "English (US)",
volume = "93",
pages = "E1171--E1179",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "12",
}